PURPOSE:Fingolimod (FTY720) is a sphingosine-1 phosphate-receptor (S1PR) modulator recently approved as a once-daily oral therapy for relapsing multiple sclerosis (MS) in many countries. As S1PRs are widely expressed, including in heart and lung tissues, this study investigated the possible effects of fingolimod on heart-rate circadian rhythm and pulmonary function. METHODS:Healthy volunteers (n = 39) were randomized to receive fingolimod 0.5 mg, 1.25 mg, or placebo for 14 days. Heart rate and measures of cardiac and pulmonary function were assessed during the study. RESULTS:Mean heart rate for the first 12 h postdose was lower for both fingolimod than for placebo groups (p < 0.001) and remained 10-15 bpm lower than placebo until day 14 (p < 0.05). Heart rate circadian rhythm, cardiac output, stroke volume, and systemic vascular resistance were similar among treatment groups throughout the study. There was no evidence of an effect of fingolimod on pulmonary function. Absolute lymphocyte counts decreased by approximately 70% from baseline in both fingolimod groups (day 14) and began to increase within 14 days of stopping treatment. CONCLUSIONS: In healthy volunteers treated for 14 days, once-daily fingolimod doses of 0.5 mg and 1.25 mg had no effect on cardiac or pulmonary function beyond a transient decrease in heart rate at treatment initiation.
RCT Entities:
PURPOSE:Fingolimod (FTY720) is a sphingosine-1 phosphate-receptor (S1PR) modulator recently approved as a once-daily oral therapy for relapsing multiple sclerosis (MS) in many countries. As S1PRs are widely expressed, including in heart and lung tissues, this study investigated the possible effects of fingolimod on heart-rate circadian rhythm and pulmonary function. METHODS: Healthy volunteers (n = 39) were randomized to receive fingolimod 0.5 mg, 1.25 mg, or placebo for 14 days. Heart rate and measures of cardiac and pulmonary function were assessed during the study. RESULTS: Mean heart rate for the first 12 h postdose was lower for both fingolimod than for placebo groups (p < 0.001) and remained 10-15 bpm lower than placebo until day 14 (p < 0.05). Heart rate circadian rhythm, cardiac output, stroke volume, and systemic vascular resistance were similar among treatment groups throughout the study. There was no evidence of an effect of fingolimod on pulmonary function. Absolute lymphocyte counts decreased by approximately 70% from baseline in both fingolimod groups (day 14) and began to increase within 14 days of stopping treatment. CONCLUSIONS: In healthy volunteers treated for 14 days, once-daily fingolimod doses of 0.5 mg and 1.25 mg had no effect on cardiac or pulmonary function beyond a transient decrease in heart rate at treatment initiation.
Authors: Ludwig Kappos; Jack Antel; Giancarlo Comi; Xavier Montalban; Paul O'Connor; Chris H Polman; Tomas Haas; Alexander A Korn; Goeril Karlsson; Ernst W Radue Journal: N Engl J Med Date: 2006-09-14 Impact factor: 91.245
Authors: John M Kovarik; Stefan Hartmann; Michael Bartlett; Gilles-Jacques Riviere; Daniel Neddermann; Yibin Wang; Andreas Port; Robert L Schmouder Journal: Biopharm Drug Dispos Date: 2007-03 Impact factor: 1.627
Authors: D D Pinschewer; A F Ochsenbein; B Odermatt; V Brinkmann; H Hengartner; R M Zinkernagel Journal: J Immunol Date: 2000-06-01 Impact factor: 5.422
Authors: Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Sakari Simula; Tomi Laitinen; Tiina M Laitinen; Tuula Tarkiainen; Juha E K Hartikainen; Päivi Hartikainen Journal: J Neuroimmune Pharmacol Date: 2015-06-20 Impact factor: 4.147
Authors: Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Steve Roof; Jason G Harb; Greg Ferenchak; Ann-Kathrin Eisfeld; James R Van Brocklyn; Roger Briesewitz; Sahar A Saddoughi; Kyosuke Nagata; Robert Bittman; Michael A Caligiuri; Omar Abdel-Wahab; Ross Levine; Ralph B Arlinghaus; Alfonso Quintas-Cardama; John M Goldman; Jane Apperley; Alistair Reid; Dragana Milojkovic; Mark T Ziolo; Guido Marcucci; Besim Ogretmen; Paolo Neviani; Danilo Perrotti Journal: Blood Date: 2013-08-07 Impact factor: 22.113
Authors: Max J Hilz; Tassanai Intravooth; Sebastian Moeller; Ruihao Wang; De-Hyung Lee; Julia Koehn; Ralf A Linker Journal: PLoS One Date: 2015-07-06 Impact factor: 3.240